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ABSTRACT
Objectives: Prenatal interventions in LUTO (lower urinary tract obstruction) usually are still question of a debate between 
gynaecologist and paediatric nephrologist. We aimed the study to assess the early survival rate and renal outcome in 
LUTO foetuses.
Material and methods: The study was a prospective data analysis of 39 foetuses from singleton pregnancies. All preg-
nant women with LUTO in the foetus were qualified for VAS based on a local practice. The mean time of first urine analysis 
ranged between 13–30 weeks of pregnancy. Primary end-point analysis included live birth, 28d-survival, pulmonary and 
renal function assessment in neonatal period. 
Results: From initial number of 39, six patients miscarried before the procedure was performed. Overall, 33 VAS were per-
formed at the mean 21 week of pregnancy (range 14–30 weeks). 25/39 foetuses survived until delivery. Three neonates died in 
first 3 days of life. In the first month 3 children required peritoneal dialysis, but at 28 day all children were dialysis-free. Overall 
survival rate at 28 day was 56%. Renal function preservation of the initial group (39) turned out to be low — 18% (7/39).
Conclusions: Our study showed average survival curves and complications. LUTO in the foetus had mostly unfavourable 
outcome in the neonatal period. The prenatal intervention did not increase it significantly and did not guarantee the 
preservation of normal kidney function. 
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INTRODUCTION
Proper diagnosis and prenatal treatment of foetal lower 
urinary tract obstruction (LUTO) still constitutes a great 
challenge for obstetricians and neonatologists despite the 
significant progress in last 30 years [1, 2]. Clinically signifi-
cant LUTO is detected in 1:10–20 000 pregnancies [3] . Male 
foetuses with posterior urethral valves (PUV) prevail, but 
female foetuses may also develop LUTO due to urethral 
stenosis or atresia [3, 4]. 
According to the latest studies success rates measured 
by 2-y survival ranges from 21–72%, depending on the study 
intervention [5, 6]. It might be assumed that the long-term 
renal function depends mostly on the number of nephrons, 
dysplastic and cystic changes that had occurred before urine 
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Table 1. Prenatal characteristics of the study group. Continuous data presented as median value and min–max range)
All foetuses
N = 39
Survivors at 28d. 
n = 22
Non–Surivors  
n = 17 Statistical difference
Mother age [y] 29 (18–38) 29 (18–38) 29 (19–37) > 0.05
Pregnancy 1.5 (1–5) 2 (1–5) 1.5 (1–3) > 0.05
Week of diagnosis of LUTO 18 (12–30) 18 (13–30) 17 (12–21) > 0.05
AFI  [cm] 6 (0–21) 8 (0–21) 3 (0–21) 0.04
Week of intervention – shunting 21 (14–30) 22 (14–30) 20 (16–23) 0.06
Number of shunts/patient 1.5 (1–5) 2 (1–5) 1.5 (1–3)* > 0.05
Need for amnioinfusions 18/39 12/22 6/17 NA
* only 11 were shunted; AFI — amniotic fluid index; LUTO — lower urinary tract obstruction
production start. This may be related to multiple genetic, 
epigenetic and environmental factors of early pregnancy, 
before any intervention is possible [7].
Prenatal interventions in LUTO usually comprise vesi-
co-amniotic shunting (VAS) or laser valve ablation, which in 
selected cases are accompanied by amnioinfusions. These 
procedures may prevent pulmonary hypoplasia and progres-
sion of irreversible renal damage [3]. There was at least one 
attempt to prove the effectiveness of VAS in randomised 
controlled trial, but it did not show enough strength to draw 
firm conclusions [8]. However, some observational data and 
metaanalyses suggested that VAS may improve perinatal 
survival, but without significant influence of renal survival [9]. 
Because of the lack of randomised control trials and 
controversies about the interventions, there is still a place 
for observational trials in this field. Thus, the aim of our study 
was to assess the neonatal outcome in an unselected cohort 
of prenatally detected LUTO qualified for VAS.
MATERIAL AND METHODS
The study was a prospective observational trial (y.:2016–
2018) led in the tertiary multidisciplinary reference centre 
on neonatal outcome in the cohort of foetuses diagnosed 
prenatally with LUTO and qualified for prenatal intervention. 
The study team comprised of 10 physicians (obstetricians, 
neonatologists, urologists and nephrologists), who were 
trained in the protocol. 
The study was accepted by the Local Ethics Committee 
of Polish Mother’s Memorial Hospital Research Institute 
(No:1/2016) and conducted according to the Declaration 
of Helsinki. All the pregnant women, and later parents and 
guardians of the neonates gave informed consents for par-
ticipation in the study.
Inclusion criteria of the study were:
1. obstructive uropathy by ultrasound with megablad-
der detected in at least 2 separate examinations with 
or without hydronephrosis, with normal or reduced 
amniotic fluid volume
2. singleton pregnancy
3. patient consent for prenatal intervention
Foetuses with multiple genetic abnormalities and/or 
abnormal karyotype were excluded from further evaluation. 
Study group characteristics 
All the patients diagnosed with LUTO between January 
2016 and December 2017 in whom the LUTO was detected 
by repeated ultrasound were offered a prenatal intervention 
of VAS and a prenatal and postnatal follow-up in the refer-
ence centre. The decision of prenatal intervention was based 
on clinical experience of an experienced obstetric team and 
the parents (local criteria for intervention: enlarged blad-
der, reduced amniotic fluid, hydronephrosis — uni or bilat-
eral). The urinary analysis was done but did not constitute 
a contraindication for the intervention. Parenchymal kidney 
changes were noted but did not influence the qualification. 
Finally, 39 patients entered the study. Clinical characteristics 
of patients is presented in Table 1. 
Preoperatively, a detailed ultrasound examination (Vo-
luson E8, GE Healthcare) was carried out to confirm the 
diagnosis of obstructive uropathy and exclude any other 
major defects. Obstructive uropathy was diagnosed by the 
presence of enlarged bladder (megabladder) with or with-
out “keyhole” sign. A diagnostic “keyhole” sign is seen in PUV, 
indicating continuity between distended bladder and the 
dilated posterior urethra proximal to the valves. Changes 
in renal parenchyma — increased echogenicity or struc-
ture and cyst formation were also described (Tab. 2). Oli-
gohydramnios was defined by single deepest pocket of 
less than 2 cm. 
Vesico-amniotic shunting procedure
Ultrasound scanning was used to obtain a transverse 
section of the enlarged bladder and define the appropriate 
site of entry on the maternal abdomen which was infiltrated 
with local anesthetic (10 mL of 1% lignocaine) down to the 
myometrium. Under continuous ultrasound guidance, the 
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shunt (diameter 2 mm, length 12 cm; Rocket KCH Fetal Blad-
der Catheter, Washington, United Kingdom) was inserted. 
In the foetal urine selected markers of prognosis were 
assessed: sodium (normal < 100 mmol/l), chloride (nor-
mal < 90 mmol/L), β2microglobulin (SO-314.501 LIAISON 
beta 2- microglobulin; normal < 4.0 mg/L) concentration and 
urine osmolarity (normal < 200 mOsm/kg/H2O). The values 
of these predictive indices in the study group are given in 
Table 3. They were analysed according to the criteria cited 
in the last review by Smith-Harrison [3]. Pregnancy duration 
and delivery procedures were analysed according to the 
outcome (demise, termination, still birth, live birth).
Neonatal assessment
After delivery the neonate was assessed with basic 
anthropometry and Apgar score. On the 4th day clinical 
and biochemical variables were analysed: survival renal 
function (eGFR and absolute creatinine [10]), albuminuria 
(albumin/creatinine ratio: ACR) and urine output, pulmonary 
function (ventilation dependency, clinical and radiological 
signs of pulmonary hypoplasia) and central nervous system 
(CNS) injury. Within first 28 days LUTO was confirmed/ex-
cluded by micturating cystogram/cystoscopy. Urologic in-
terventions also were assessed. Clinical data were gathered 
with regard to the urine output, ventilation support and 
vasopressors need. Blood pressure was measured with oscil-
lometric devices to exclude hypertension.
Urinary tract was assessed by a radiologist experienced 
in paediatric ultrasound. The Samsung RS80 device with 
convex/microconvex and linear probes were used. 
Kidney injury was measured by serum creatinine (ELISA) 
compared with reference values of Rudd et al. [10] eGFR 
calculation was performed according to the Schwartz for-
mula (with k value of 0.33 for neonates) and presence of 
albuminuria (albumin/creatinine ratio — ACR) [11]. Albumin 
excretion was compared to the data obtained in preterm 
babies from the study of Gubhaju et al [12]. Children were 
tested for presence of acidosis. The study had 2 primary 
endpoints: survival and kidney injury symptoms at 28th 
day of life. 
Statistical methods 
Data analysis was performed using Statistica package 
version 12 (StatSoft Inc., USA) with medical add-in. All pa-
rameters were tested for normal distribution using Shap-
iro-Wilk W test and were presented as means with stand-
ard deviation. Comparisons of differences in characteristics 
between two groups (survivors and non-survivors) were 
performed using the Student’s t-test and Mann-Whitney 
U test depending on the distribution of data. The differences 
between proportions were evaluated by chi-squared test.
The assessment of the validity of prenatal markers for 28-
day survival was performed with discriminative analysis and 
a probabilistic predictive Naïve Bayes model. A Wilks lambda 
test was used to test for significant differences between 
the groups on the individual predictor variables. A signifi-
cance level of p < 0.05 was considered significant. A receiver 
operating characteristic (ROC) curve with sensitivity and 
precision were applied to examine the correctness of the 
predictive model. The Kaplan-Meyer estimator was used 
for estimation the survival function.
RESULTS
Amongst the study group all pregnant women accepted 
the prenatal intervention. However, six patients miscarried 
before the procedure was performed. Overall, 33 VAS were 
performed at the mean 21 week of pregnancy (range 14–
30 weeks). No pregnancy lost was noted as a complication 
of prenatal interventions. In 6 cases there was a dislodge-
ment/blockage of the shunt and procedure was repeated. 
Mean number of interventions was 1.5/foetus (range 1–5) 
— detailed data are presented in Figure 1. In 18 cases prior 
Table 2. Initial description of ultrasound images in the study group
Megabladder 
only
Megabladder and 
hydronephrosis
Only bilateral 
hydronephrosis
Renal parenchymal 
changes — 
echogenicity
Renal cysts 
present 
Renal cysts or changes 
in echogenicity Oligohydramnios
19/39
51%
14/39
36%
5/39  
13%
22/39
56%
25/39
64%
29/39
74%
30/39
85%
Table 3. Biochemical predictive factors in the fetal urine analysis (median and min–max range)
All subjects Survivors at 28 d Non–survivors Statistical difference
sodium [mmol/L] 104 (50–146) 91 (50–146) 116 (50–127) 0.17
chloride [mmol/L] 84 (5–145) 80 (5–146) 95 (66–114) 0.17
B2–microglobuline 7.1 (0.4–24.7) 6.7 (0.4–17.0) 10.7 (2.2–24.7) 0.14
Osmolarity [mOsm/kg H2O] 223 (96–289) 187 (96–289) 241 (164–264) 0.08
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to shunt insertion, amnioinfusion was performed due to 
technical difficulties (anhydramnios). Clinical characteristics 
of pregnancies are presented in Table 1.
20 patients were confirmed by postnatal evaluation to 
have PUV. In 10 foetuses diagnosis was confirmed by patho-
morphology evaluation. There were also 1 urethral atresia 
(UA, in female) and in one no significant malformation of 
urinary tract was detected. There were 8 intrauterine deaths 
at mean age of 26 hbd (range 18–29). The deaths were noted 
with functioning shunts in a mean time of 3 weeks after 
shunting. 25 children were born at the mean age of 34 weeks 
(range 24–39 hbd) with mean Apgar score of 8 (range 1–10).
Anthropometrical, clinical and biochemical data of the 
live-born children with comparison of non-survivors and 
survivors at 28 day are presented in Table 4. We observed 
that those neonates who died after birth had lower birth 
age, body mass, head circumference and Apgar score.
Radiological and clinical investigations confirmed LUTO 
in 24/25 newborns (PUV-23, UA-1). 6 children had urinary 
tract diversions in neonatal period and 16 cystoscopy with 
electroresection of the PUV within 28 days. No patient had 
hypertension. 21/25 required intensive care with cardiac 
support with vasoactive amines and ventilation support 
(for the mean 2.4 days — range 1–20). Mean ICU stay was 
36 days (1–150 d.). Radiological features of lung hypoplasia 
were detected in 6/25 neonates. We noted 3 deaths within 
first 3 days of life because of cardio-pulmonary insufficiency 
with lung hypoplasia. At 4th day 18/22 required mechanical 
ventilation but at 28th day all children were free of me-
chanical support. In 2/22 clinical features of pulmonary 
hypoplasia were present at this time. No child amongst 
those who survived required oxygen supplementation at 
the end of neonatal period.
Renal function was compromised in 13/22 of subjects 
who survived with mean eGFR on 4th day of 16.2 (4–47) 
mL/min/1.73 sqm. Serum creatinine was elevated also in 
13/22 when compared to the reference from 7th day pub-
lished by Rudd. [10]. 12 out of 22 neonates had significant 
acidosis and 11/22 proteinuria (mean: 102; r: 25–339 mg/dL). 
ACR was significantly elevated in 86% of cases (Tab. 4).
Three out of 25 (12%) children were treated with perito-
neal dialysis at 4th day (for 3 to 19 days) – and all survived, 
while no one required it at the 28th day because of renal 
function improvement. 
Overall survival rate at 28th day was 56% among 
whole LUTO group of patients. In PUV patients it was 
lower 20/37 — 54%, but in those who underwent VAS 
— 20/30 — 66%.
Qualied for the study n = 39
Prenatal demise before VAS
n = 6
Prenatal VAS
n = 33
Intrauterine death
n = 8
Perinatal death
n = 3
Female subject or PUV not
con rmed n = 2
Alive with PUV at 28 d
n = 20
Live-birth
n = 25
Alive at day 4
n = 22
Figure 1. Outcome flowchart in the study group
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Kidney injury markers were also tested at the end of 
neonatal period. 12/22 (54%) neonates had impaired eGFR 
(13/33 elevated creatinine) with eGFR of 24 (range 5–19) 
mL/min/1.73 m2BSA, 18 (82%) had increased albumin 
excretion (mean 5.4 range 0.05–13.5 mg/mg). When the 
combined renal survival (free of any injury) of the initial 
group (39) was analysed, it turned out to be significantly 
low — 18% (7/39). When only who survived neonatal period 
were qualified the percentage rose to 32% (7/22). 
When we compared the data of foetuses (children) who 
survived with the other only several significant differences 
were detected. Normal foetal urine osmolarity was detected 
in 10/22 foetuses who survived and in only 1/17 who did not 
(p = 0.03). We also found that in the former group AFI was 
higher (8 vs. 4, p = 0.04). Borderline significance was achieved 
with the age of the first VAS (21 vs. 19 hbd, p = 0.056).
We aimed at determining any prenatal marker of 28-day 
survival in the study group. Clinical markers of the pregnan-
cy and VAS intervention, sodium, chloride, β2-microglobulin 
urine concentration, urine osmolarity, amniotic fluid index, 
presence of dysplastic changes in renal parenchyma were 
initially included. Using common statistical tests and dis-
criminant analysis, we only found that the survival rate 
was higher in those who were shunted. To validate the 
discriminative quality of shunting for prediction of survival 
we used a probabilistic predictive Naïve Bayes model. The 
assessed sensitivity the model was of 0.718 and precision of 
0.812 with a low value of AUC equalled 0.528. The combina-
tion AFI, shunting and normal urine osmolarity assessed 
at the moment of diagnosis were characterised similarly: 
sensitivity of 0.744, precision of 0.743 with AUC 0.850. No 
other single predictor or combination of predictors were 
recorded as prognostic.
In the Kaplan Meyer analysis at 28th day we observed 
that foetuses with at least 2 (out of 3 standard) abnormalities 
in the urine analysis differed with regard to outcome (Fig. 2).
DISCUSSION 
We aimed our study to assess short-term outcome in 
LUTO. The patients remained under care of the same team 
Table 4. Clinical and biochemical characteristics of neonates from the study group (median and min–max range)
All subjects Survivors at 28d Non-survivors (demise/stillbirth/death) Statistical difference
OU confirmed 38/39 21/22 10/17* NA
Gender (M:F) 38/1 21/1 17/0 NA
Birth age [weeks] 33 (24–39) 35 (29–39) 30 (24–32) 0.001
Apgar score at 5 min. 8 (1–10) 9 (4–10) 6 (1–6) 0.001
Weight [g] 2.4 (0.5–4.4) 2.6 (1.5–4.4) 1.8 (0.5–1.9) 0.005
Lenght [cm] 47 (28–57) 49 (41–57) 41 (28–42) 0.002
Head circumferrence 31 (15–38) 32 (27–38) 30 (15–32) 0.002
Ventilation support after birth [%] 21/25 18/22 3/3 NA
Oxygen dependency at birth [%] 24/25 21/22 3/3 NA
Pulmonary hypoplasia at 28 d [%] NA 2/22 NA NA
ACR at 4 d [mg/mg] NA 7.7 **(2.6–30) NA NA
Serum creatinine at 4d [mg/dL] NA 1.7  (0.5–1.74) NA NA
eGFR at 4 d. [mL/min/1.73 BSA] NA 10 (4–37) NA NA
ACR at 28 d [mg/mg] NA 4.7***  
(0.05–13.5) NA NA
Serum creatinine at 28d [mg/dL] NA 0.95 (0.25–4.7) NA NA
eGFR at 28d. [mL/min/1.73 BSA] NA 20.6 (5–79) NA NA
Urine output [mL/kg/h] at 4 d NA 3.4 (1.0–7.5) NA NA
Dialysis need [%] 3/25 3/22 0/3 NA
Dialysis lenght [d] 3–19 NA NA NA
ICU stay [d] NA 19 (1–150) NA NA
Acidosis at 28day NA 9/22 NA NA
HCO3 [mmol/l] NA 10 (17–25) NA NA
* — only 10 were analysed by pathomorphology; ** —  maximum excretion for preterm 0.21 mg/mg (22 mg/mmol) by Gubhaju et al. [12]; *** — maximum excretion 
for preterm 0.11 mg/mg (15 mg/mmol) Gubhaju et al. [12]; eGFR — estimated glomerular filtration rate; NA — not applicable; OU — obstructive uropathy
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until the end of pregnancy and at least up to 28th day after 
delivery.
Prenatal diagnosis was confirmed in 87.6% cases. 
We found that overall survival rate in LUTO qualified for shunt-
ing at 28d was 56%, however when only shunted foetuses 
were included it rose to 66%. When the renal function pres-
ervation was analysed, we showed that significant number 
of children had compromised eGFR at 4th day from delivery 
with need for temporary dialysis in 3/22. Proteinuria in this 
group of patients was also a frequent marker of kidney injury. 
Only 18% of initially qualified subject survived until neonatal 
period with no kidney injury (eGFR decrease or significant 
proteinuria). VAS preserved renal function in 7/22 children 
who survived (32%). The overall 28d survival rate was similar 
to those reported in other single and multicentre trials.
The analysis conducted by Morris et al. done on basis of 
PLUTO randomised controlled trial and prospective observa-
tional cohort study reported 28 day survival rate as 50% and 
40% respectively [6]. What was surprising, this survival rate 
was significantly lower than in the conservatively managed 
patients. Survival to 28 days after delivery was higher in the 
conservative-management group, at 69% (24/35), compared 
to 40% (4/10) in the VAS group (p = 0.02). Compared to 
the conservative-management group of the trial, a higher 
proportion of women in this registry opting for conserva-
tive management had a normal amniotic fluid volume at 
diagnosis (p = 0.05) and a diagnosis of LUTO ≥ 24 weeks’ 
gestation (p = 0.003). On multivariable logistic regression 
analysis, these variables showed a significant association 
with perinatal survival (p < 0.001) [6]. 
Ruano group assessed the 2-y outcome after foetal 
intervention in 50 patients with LUTO. They found PUV in 
31 (62%) foetuses, urethral atresia (UA) in 14 (28%) foetuses, 
and urethral stenosis (US) in 5 (10%) foetuses. There were no 
survivors in the UA group. Eleven (22.9%) infants died during 
the neonatal period because of prematurity, lung hypoplasia 
or renal failure [13]. Short term survival rate in all abnormali-
ties was 36% (18/50) which is comparable to our data. 
Ethun et al. [14] analysed outcome of 14 patients after 
prenatal intervention of LUTO and showed similar results 
to our observation with regard to success and complica-
tions. Jeong et al. [15] showed among the 32 foetuses exam-
ined that: 5 died because of termination of pregnancy, and 
2 died in utero. Three neonatal deaths occurred, resulting in 
an overall perinatal survival rate of 68.8% (22 of 32). Fontanella 
et al. [16] analysed the data of foetuses at high-risk of isolat-
ed LUTO and managed conservatively. The survival rate was 
42% and was similar to our observation. Martinez et al. per-
formed 20 fetal PUV ablations at the median gestational age 
of 18.1 weeks (range 15.0–25.6). Overall, there were 9 (45%) 
terminations of pregnancy and 11 women (55%) delivered 
a liveborn baby at a mean gestational age of 37.3 (29.1–
40.2) weeks. No infants who survived developed pulmo-
nary hypoplasia and all were alive at 15–110 months [17]. 
Johnson et al. [18] in the cohort study on LUTO in USA re-
ported even higher percentage of perinatal survival (97%), 
but surprisingly dialysis was required in 32% of patients. 
Ruano et al. analysed retrospectively a cohort of 111 foe-
tuses with LUTO. They showed that the probability of survival 
was significantly higher with foetal cystoscopy and VAS when 
compared to no intervention [adjusted relative risk (ARR) 
1.86 (95% CI, 1.01–3.42; p = 0.048) and ARR, 1.73 (95% CI, 
1.01–3.08; p = 0.04) respectively]. Unfortunately, there was 
no statistically significant chance for maintaining normal 
kidney function in short and long-term observation. How-
ever, when they analysed only PUV patients, the situation 
turned out to be more optimistic. Foetal cystoscopy was 
effective in improving both the 6-month survival rate and 
renal function [ARR 4.10 (95% CI, 1.75–9.62; p < 0.01)] and 
2.66 [(95% CI, 1.25–5.70; p = 0.01) respectively] while VAS was 
associated only with an improvement in the 6-month survival 
rate [ARR 3.76 (95% CI, 1.42–9.97; p < 0.01)] with no effect 
on renal function (ARR 1.03 [95% CI, 0.49–2.17, p = 0.93]) [5].
We found that shunting with VAS was successful in pre-
vention of renal injury in the neonatal period only in 18% of 
patients from the initially qualified group. From those who 
survived 32% were free of any injury. In the study of Martinez 
et al. [17] on 20 PUV ablations, 8 (40% of all foetuses, 72.7% 
of newborns) had normal renal function and 3 (27.3%) had 
CKD awaiting renal transplantation. They assessed the kid-
ney injury by eGFR decrease with no data on proteinuria. 
Similarly, Ruano et al. [13] reported that among the infants 
with PUV 17/30 (56.7%) survived and 13/17 (76.5%) had 
normal renal function at 1 year of life; 15/28 (53.6%) survived 
and 11/15 (73.3%) had normal renal function at 2 years. 
Our study showed that classical prognostic factors did 
not differ between the survivors and non survivors group. 
Figure 2. Kaplan-Meyer survival curves for all subjects and adjusted 
to the presence of negative prognostic factors in fetal urine analysis
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Only a combination of predictors (shunting, urine osmolarity 
and AFI) showed little value in this prediction. In the Ka-
plan-Meier curve analysis foetuses with at least 2 increased 
classical biochemical parameters (osmolarity, sodium and 
chloride concentration) had lower survival rate. These results 
are concordant with other studies, where only combined 
prenatal factors were potentially qualified as significant in 
multivariate analysis [5, 14, 18, 19]. 
We are aware of the weaknesses of the study. The number 
of patients included was relatively small, but that was a single 
centre analysis. Only multicentre studies presented signifi-
cantly higher number of patients. Furthermore, there was no 
comparator (conservative treatment) arm in the study group, 
nor the randomisation was possible. However, this weakness 
may turn into some strength. Because of specific treatment 
policy of the centre and profile of the country our cohort was 
complete and all of the pregnant women with LUTO diagnosis 
referred in second trimester were proposed an intervention 
with no option of termination of pregnancy based on patient 
decision. The number of patients at the first sight would look 
low, but when it is compared to single arms of PLUTO studies 
and other papers it could be qualified as one of the largest pro-
spective cohort of VAS ever published [6]. One can postulate 
that the location of neonatal and urology-nephrology centre 
in once place increases the value of observation and quality 
of data. The data gathered in the neonatal period concern-
ing comorbidities and development should enrich the value 
of observation. The broad range of VAS intervention (up to 
30 week) also decreases the precision and value of observation 
but similar approach was also presented by other authors.
CONCLUSIONS
Our study led to clinically important conclusions that 
pregnancies with LUTO fulfilling criteria for prenatal inter-
ventions had significant percentage of unfavourable out-
come. The full prevention of the kidney injury in live-born 
subject was difficult to achieve. However, the need of early 
neonatal dialysis was relatively low.
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